Covid-19: La FDA revocó la autorización de bebtelovimab de Lilly, Evusheld de AstraZeneca, sotrovimab de GSK y REGEN-COV de Regeneron. FDA revoked the authorization for Lilly's bebtelovimab, AstraZeneca's Evusheld, GSK's sotrovimab and Regeneron's REGEN-COV.

 La FDA revocó la autorización de bebtelovimab de Lilly, Evusheld de AstraZeneca, sotrovimab de GSK y REGEN-COV de Regeneron. FDA revoked the authorization for Lilly's bebtelovimab, AstraZeneca's Evusheld, GSK's sotrovimab and Regeneron's REGEN-COV.

https://www.medscape.com/s/viewarticle/us-fda-revokes-authorization-four-covid-antibody-drugs-2024a1000p08

Reuters Health Information © 2024 Reuters Ltd.

Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.